
ARS Pharmaceuticals fell 46.9% from $7.32 to $3.89, behind the S&P 500's +13.3%. Its worst day was Jun 25 (−23.9%), and its low came Nov 5 at $2.65.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ARS Pharmaceuticals shares rose 15.6%, while the S&P 500 rose 0.9%.
+15.6% · S&P 500 +0.9%
ARS Pharmaceuticals closed at its highest level of the year, 78.4% above where the year started.
+19.3%, the year's best day · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
EPS of $-0.42 beat the $-0.46 estimate on $28.1M revenue (est. $25.6M).
−0.1% · S&P 500 +0.9%
EPS of $-0.61 missed the $-0.53 estimate on $22.7M revenue (est. $22.1M).
−6.5% · S&P 500 −1.2%
Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026
−23.9%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 +0.1%
EPS of $-0.63 missed the $-0.50 estimate on $33.7M revenue (est. $31.4M).
−7.4% · S&P 500 −0.2%
EPS of $-0.36 missed the $-0.33 estimate on $37.7M revenue (est. $42.1M).
+5.3% · S&P 500 +0.3%
Where it ended: a close of $3.89 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-0.28, revenue est. $26.4M).
Nothing in the past 12 months.
All SPRY dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SPRY and SPY from Benzinga historical bars. Not investment advice.